Mi­to­conix lands $20M to de­vel­op neu­rode­gen­er­a­tive plat­form out of Stan­ford; RaNA gets a new name fol­low­ing mR­NA deal with Shire

→ Mi­to­conix has a neu­rode­gen­er­a­tion plat­form tech from Stan­ford and a base in Is­rael from which it plans to push its lead ther­a­py in­to clin­i­cal test­ing with the help of a $20 mil­lion A round. The sci­ence comes from the lab of Stan­ford’s Daria Mochly-Rosen, who has been study­ing the ef­fect of ex­ces­sive fis­sion on mi­to­chon­dria. Their lead drug is the pre­clin­i­cal MTC-1203, an in­hibitor for fis­sion that’s been put through an­i­mal tests for Hunt­ing­ton’s dis­ease. The fledg­ling biotech al­so be­lieves it can work in a va­ri­ety of oth­er neu­rode­gen­er­a­tive dis­eases like Parkin­son’s. Remiges Ven­tures led the round with help from Or­biMed, De­men­tia Dis­cov­ery Fund, Ar­ix Bio­science, RMGP Bio-Phar­ma in­vest­ment Fund and oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.